Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Cleo Diagnostics Advances Ovarian Cancer Test Validation, Screening Program Clears Early Benchmarks

COV: $0.295 -1.67% · MC: $38M

Cleo Diagnostics received its first production batch of test kits and began analytical validation, while engaging a U.S. laboratory for pivotal clinical testing; it continues to target an FDA submission in the first half of 2027. Its screening program’s initial retrospective study exceeded the company’s stated performance benchmarks, an early research result that still requires confirmation in larger, intended-use populations. Cash stood at approximately A$4 million at quarter-end.

Source announcements: 2026-10-30 16:11 to 2026-10-30 16:11 Sydney time
Story updated 2026-10-30 16:19 Sydney time
SourcesQuarterly activities and cashflow report
Comments